CREBtide TFA

CAS: F: C73H129N29O19.xC2HF3O2 W: 1716.99 (free acid)

CREBtide TFA is a CREB (cAMP response element binding protein)-like peptide. CREBtide TFA a synthetic 13 amino acid pept

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	CREBtide TFA is a CREB (cAMP response element binding protein)-like peptide. CREBtide TFA a synthetic 13 amino acid peptide, has been reported as a PKA substrate[1][2][3].
Invitro	delta-CREB is a spliced variant of cAMP response element binding protein (CREB). CREBtide (KRREILSRRPSYR), a synthetic peptide based on the phosphorylation sequence in delta-CREB. delta-CREB and CREBtide are tested as substrates of cAMP-dependent protein kinase (cAK). The apparent Km of CREBtide phosphorylation by cAK is 3.9 μM, which is 10-fold lower than that of Kemptide (Km=39 μM), the synthetic peptide substrate most often employed for cAK measurement. The Vmax values are 12.4 mumol/(min.mg) for CREBtide and 9.8 mumol/(min.mg) for Kemptide. The apparent Km of CREBtide phosphorylation by cGMP-dependent protein kinase (cGK) is 2.9 μM and the Vmax value is 3.2 mumol/(min.mg). Both delta-CREB and CREBtide are phosphorylated at a much slower rate by cGK as compared with cAK, implying that the high cAK/cGK specificity exhibits by delta-CREB is retained by the peptide[2]. 0 --> CREBtide TFA 相关抗体:
Name	CREBtide TFA
Sequence	Lys-Arg-Arg-Glu-Ile-Leu-Ser-Arg-Arg-Pro-Ser-Tyr-Arg
Shortening	KRREILSRRPSYR
Formula	C73H129N29O19.xC2HF3O2
Molar Mass	1716.99 (free acid)
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Wu J, et al. A microPLC-based approach for determining kinase-substrate specificity. Assay Drug Dev Technol. 2007 Aug;5(4):559-66. [2]. Colbran JL, et al. cAMP-dependent protein kinase, but not the cGMP-dependent enzyme, rapidly phosphorylates delta-CREB, and a synthetic delta-CREB peptide. Biochem Cell Biol. 1992 Oct-Nov;70(10-11):1277-82. [3]. Harum KH, et al. Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation. Neurology. 2001 Jan 23;56(2):207-14.

Gossypetin 3′-O-glucoside